Lv1
40 积分 2026-02-20 加入
Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial
19天前
已完结
A Phase 1B Trial in GBA1‐Associated Parkinson's Disease of BIA‐28‐6156, a Glucocerebrosidase Activator
1个月前
已完结
Prasinezumab: what have we learned from PASADENA and PADOVA?
1个月前
已完结
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study
1个月前
已完结
New evidence on the clinical, genetic, and biochemical bases of GBA1-Parkinson's disease: prospects for treatment
1个月前
已关闭
Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis
1个月前
已完结
Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial
2个月前
已完结
Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022
2个月前
已完结
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
2个月前
已完结
European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs
2个月前
已完结
皖公网安备34019202002308
